| Q34206939 | A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies |
| Q46725155 | ABO incompatible liver transplants: room for cautious optimism |
| Q91725102 | ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis |
| Q33422561 | ABO-compatible liver allograft antibody-mediated rejection: an update |
| Q90705931 | ABO-incompatible deceased donor pediatric liver transplantation: Novel titer-based management protocol and outcomes |
| Q93140245 | ABO-incompatible liver transplantation: Is it a viable option with modern innovation? |
| Q34156791 | ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy. |
| Q35546323 | Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features |
| Q41845634 | Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience |
| Q42574231 | Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers |
| Q37248719 | Aspects of liver transplant pathology with emphasis on rejection and its mechanisms |
| Q51016759 | Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. |
| Q48320935 | Computed tomography findings in ABO-incompatible living donor liver transplantation recipients with biliary strictures. |
| Q28077320 | Current techniques for AB0-incompatible living donor liver transplantation |
| Q42574211 | Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury |
| Q34396490 | Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys |
| Q55332524 | Feasibility of using marginal liver grafts in living donor liver transplantation. |
| Q39965408 | Feasible usage of ABO incompatible grafts in living donor liver transplantation |
| Q92606381 | Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation |
| Q34304815 | Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts |
| Q34351946 | Increased bile duct complications in liver transplantation across the ABO barrier |
| Q57787330 | Ischemic Damage Represents the Main Risk Factor for Biliary Stricture After Liver Transplantation: A Follow-Up Study in a Danish Population |
| Q42094566 | Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model |
| Q34962253 | Liver transplantation (1). |
| Q44669532 | Living donor liver transplantation with special reference to ABO-incompatible grafts and small-for-size grafts |
| Q37848741 | Management of ABO-incompatible living-donor liver transplantation: past and present trends |
| Q52940132 | Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. |
| Q42695184 | Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis |
| Q34280929 | Pretransplant assessment of human liver grafts by plasma lecithin: cholesterol acyltransferase (LCAT) activity in multiple organ donors |
| Q33808643 | Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis |
| Q34289182 | Red cell antibody problems in 1000 liver transplants |
| Q39444886 | Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation. |
| Q34422862 | The biological basis of and strategies for clinical xenotransplantation |
| Q34858611 | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis |
| Q85642885 | The reduction rate of serum C3 following liver transplantation is an effective predictor of non-anastomotic strictures |